Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kellie Sperduto

Physician Assistant Englewood, CO Physician Assistant

NPI 1689298598 CMS profile 10777485

750 W Hampden Ave Ste 350, Englewood, CO 80110

Open in the dashboard

General payments

$5,026

192 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kellie Sperduto of Englewood, CO is reported in the CMS Open Payments database as having received $5,026 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $620 6
2024 General $236 10
2023 General $2,513 86
2022 General $842 46
2021 General $815 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kellie Sperduto
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kellie Sperduto were reported at $620. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kellie Sperduto Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $815 $132 $37–$438 $132
2022 $842 $155 $48–$522 $149
2023 $2,513 $167 $52–$557 $160
2024 $236 $178 $55–$600 $164
2025 $620 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $970 36 payments
  2. Neurocrine Biosciences, Inc. $732 14 payments
  3. ITI, Inc. $731 30 payments
  4. Sunovion Pharmaceuticals Inc. $538 31 payments
  5. Otsuka America Pharmaceutical, Inc. $523 22 payments
  6. Supernus Pharmaceuticals, Inc. $337 12 payments
  7. Janssen Pharmaceuticals, Inc $300 9 payments
  8. Alkermes, Inc. $258 7 payments
  9. Neos Therapeutics, LP $143 8 payments
  10. Lundbeck LLC $111 5 payments
  11. Other $382 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,022 191 payments
  2. Education $3 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $851 35 payments
  2. CAPLYTA $731 30 payments
  3. INGREZZA $665 11 payments
  4. LATUDA $538 31 payments
  5. REXULTI $402 15 payments
  6. QELBREE $293 10 payments
  7. INVEGA SUSTENNA $269 8 payments
  8. LYBALVI Cns $258 7 payments
  9. LYBALVI Cns $258 7 payments
  10. LYBALVI Cns $238 6 payments
  11. Other $1,486 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record